SignaGen Laboratories performs adenovirus amplification using the Ad.MAX™ platform, a robust, helper-virus–free system designed for efficient rescue and high-yield amplification of recombinant adenovirus. Customer-supplied adenovirus stocks or Ad.MAX–compatible adenoviral backbone constructs are propagated in qualified HEK293-derived producer cells under optimized culture conditions, ensuring efficient viral replication while maintaining genetic stability. The Ad.MAX system relies on defined backbone vectors and proprietary packaging elements, eliminating the need for helper virus and reducing the risk of contamination.

Following amplification, adenovirus is harvested and purified using validated downstream workflows optimized for recovery and purity. Each production batch undergoes rigorous quality control, including infectious titer determination (PFU/mL), identity verification, and sterility testing. This standardized, scalable process enables SignaGen Laboratories to consistently deliver high-titer, research-grade adenovirus with reliable performance for both in vitro and in vivo applications.